Brief: Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant In Adults With Idiopathic Pulmonary Fibrosis Met Primary Endpoint
12/10/2026 11:52
BRIEF-Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant In Adults With Idiopathic Pulmonary Fibrosis Met Primary Endpoint Oct 12 (Reuters) - Bristol-Myers Squibb Company BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES PHASE 3 ALOFT-IPF TRIAL EVALUATING ADMILPARANT IN ADULTS WITH IDIOPATHIC PULMONARY FIBROSIS MET PRIMARY ENDPOINT
BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT 60 MG DOSE SHOWS STATISTICALLY SIGNIFICANT FVC IMPROVEMENT AT WEEK 52 VERSUS PLACEBO
BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT 120 MG DOSE SLOWED FVC DECLINE BUT NOT STATISTICALLY SIGNIFICANT
BRISTOL-MYERS SQUIBB COMPANY - ADMILPARANT PHASE 3 ALOFT-PPF TRIAL TOPLINE RESULTS EXPECTED EARLY 2027
Source text: ID:nBw6Hsh6na
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Bristol Myers Squibb To Showcase Next-Generation Cancer Modalities And Leadership Across Solid Tumors At Esmo 2026
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Healthcare stocks rally as investors seek safety amid tech debt worries
AstraZeneca strikes $40 million AI drug discovery deal with insitro